Table 2.
PsP (N = 31) | No PsP (N = 52) | P-value | ||
---|---|---|---|---|
Age at RT | Median, y | 10.9 | 9.5 | P = 0.35 |
Range, y | 3.9–17.0 | 1.0–17.6 | ||
N (%) | N (%) | |||
Sex | Male | 19 (61) | 27 (52) | P = 0.63 |
Female | 12 (39) | 25 (48) | ||
Histology | PA | 14 (45) | 36 (69) | P = 0.037 |
Other LGG | 17 (55) | 16 (31) | ||
WHO histologic grade | Grade I | 21 (68) | 41 (79) | P = 0.23 |
Grade II | 10 (32) | 11 (21) | ||
Tumor location | Brainstem | 7 (23) | 12 (23) | P = 0.55 |
Cerebral hemispheres | 2 (6) | 4 (8) | ||
Thalamus | 5 (16) | 8 (15) | ||
Optic pathway/hypothalamus | 8 (26) | 21 (40) | ||
Other | 9 (29) | 7 (13) | ||
Tumor lateralization | Midline | 22 (71) | 32 (62) | P = 0.63 |
Lateralized | 9 (29) | 20 (38) | ||
Surgery prior to RT | GTR | 2 (6) | 2 (4) | P = 0.68 |
STR | 12 (39) | 25 (48) | ||
Bx | 17 (55) | 25 (48) | ||
ChT prior to RT | No | 23 (74) | 28 (54) | P = 0.11 |
Yes | 8 (26) | 24 (46) | ||
RT dose | Median (Gy[RBE]) | 50.4 | 50.4 | |
Range (Gy[RBE]) | 48.6–54 | 45–59.4 | ||
N (%) | N (%) | |||
RT dose | ≤50.4 Gy(RBE) | 22 (71) | 48 (92) | P = 0.016 |
>50.4 Gy(RBE) | 9 (29) | 4 (8) | ||
RT modality | IMRT | 8 (26) | 24 (46) | P = 0.048 |
PBT | 23 (74) | 28 (54) | ||
CTV | Median (cc) | 49.6 | 53.4 | P = 0.24 |
Range (cc) | 7.6 - 200.8 | 4.5 - 429.2 |
Univariate analyses of predictors of PsP; P-values provided for univariate tests.Abbreviations: Bx, biopsy; ChT, chemotherapy; cc, cubic centimeter.